AbbVie Inc. $ABBV Stock Position Lowered by Maseco LLP

Maseco LLP lessened its position in AbbVie Inc. (NYSE:ABBV) by 33.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,511 shares of the company’s stock after selling 2,780 shares during the quarter. Maseco LLP’s holdings in AbbVie were worth $1,259,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Diversified Trust Co increased its stake in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares during the period. Permanent Capital Management LP acquired a new position in shares of AbbVie during the 3rd quarter worth $720,000. Railway Pension Investments Ltd increased its stake in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. World Investment Advisors increased its stake in shares of AbbVie by 9.4% during the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after purchasing an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co increased its stake in shares of AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after purchasing an additional 15,502 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie sued the U.S. government seeking a narrower definition of which patients qualify for a federal drug-discount program — a move investors see as an attempt to limit mandated discounts and protect revenue/margins. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data for Skyrizi and Rinvoq showcased durability, safety and label expansions that support AbbVie’s immunology growth thesis and revenue visibility. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst and dividend-focused coverage highlights ABBV’s strong cash flow and reliable dividend (Dividend Aristocrat status and recent raises), supporting investor demand for income exposure. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation (AbbVie section)
• Neutral Sentiment: Healthcare sector momentum and “trending” stock mentions (Zacks/coverage pieces) are increasing visibility and trading interest in ABBV, which can amplify moves but are not fundamental catalysts by themselves. AbbVie Inc. (ABBV) Is a Trending Stock
• Neutral Sentiment: Brand/marketing activity — Allergan Aesthetics (BOTOX® Cosmetic) programs and new AMI training center openings — support long-term aesthetics revenue but are incremental near-term. BOTOX® Cosmetic Empowers Women Entrepreneurs
• Negative Sentiment: J&J’s Tremfya reclaimed the top spot in TV drug ad spending from AbbVie, suggesting AbbVie pulled back promotional share — a potential headwind to maintaining market momentum against competitors. J&J’s Tremfya retakes TV drug ad spending crown from AbbVie
• Negative Sentiment: AbbVie placed Humira on the TrumpRx platform at a steep discount — a tactical move to maintain access/share that pressures pricing and could weigh on legacy-revenue mix. AbbVie Puts Humira on TrumpRx at Steep Discount
• Negative Sentiment: Some analysts are flagging valuation and competitive concerns; Cantor Fitzgerald trimmed its price target modestly (still overweight), reflecting mixed views on upside vs. risks. Cantor Fitzgerald price target revision note

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ABBV shares. Royal Bank Of Canada started coverage on shares of AbbVie in a research note on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Barclays assumed coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target on the stock. Finally, Morgan Stanley raised their target price on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $252.65.

Insiders Place Their Bets

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by corporate insiders.

AbbVie Trading Up 2.6%

NYSE:ABBV opened at $211.74 on Thursday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm’s fifty day simple moving average is $220.80 and its 200 day simple moving average is $224.19. The firm has a market capitalization of $374.40 billion, a PE ratio of 89.72, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the business posted $2.16 EPS. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s dividend payout ratio is 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.